Eukaryotic expression, protein purification and biological effects research of human CS1-Fc fusion protein

CHEN Ruzhang1 WANG Xitong1 LI Yanchen1 GAO Jimin1

(1.School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China 325035)

【Abstract】Signaling lymphocyte activation family 7 (SLAMF7/CS1) is a cell surface glycoprotein that is highly expressed in multiple myeloma cells. CS1 is a sensitive and specific biomarker for multiple myeloma. CAR-T cell immunotherapy is a new method for the treatment of multiple myeloma. CS1 CAR-T cell immunotherapy has good effect on relapsed refractory multiple myeloma. To detect the expression efficiency of CS1 CAR on CS1 CAR-T cells and to find an auxiliary means to CAR-T cell immunotherapy, we prepared a CS1-Fc fusion protein. First, the extracellular domain of CS1 was amplified from the existing plasmid by PCR and ligated with human IgG1-Fc fragment by overlap extension PCR. The recombinant fragment was ligated into pMH3 eukaryotic expression vector. After restriction enzyme digestion and DNA sequencing, the pMH3-CS1-Fc-his recombinant plasmid was successfully constructed. The recombinant plasmid was transfected into Chinese hamster ovary cell (CHO-S) by liposome. The expression of the CS1-Fc fusion protein in CHO-S cells was identified by flow cytometry after G418 pressure screening. Next, the CS1-Fc fusion protein was purified by nickel column. Western-blot analysis showed that molecular weight of the fusion protein was about 70 kDa. The CS1-Fc fusion protein could effectively detect the expression rate of CS1 CAR and promote the activation, proliferation and cytokine secretion of the CS1 CAR-T cells. The results will lay the experimental foundation for the in vitro detection and potentiation of CAR-T cells in multiple myeloma treated with CS1 CAR-T cell.

【Keywords】 human signaling lymphocyte activation family 7 (SLAMF7/CS1); CS1-Fc fusion protein; eukaryotic expression; CAR-T; multiple myeloma;


【Funds】 National Natural Science Foundation of China (No. 81573110) Research Foundation of National Health Commission of the People’s Republic of China (No. WKJ-ZJ-1928) Science and Technology Major Projects of Wenzhou (No. ZJ2017014) Technology Innovation and Application Development Major Projects of Chongqing (No. cstc2019jscx-msxm X0431)

Download this article

(Translated by HE Z)


    [1] Al-Hujaily EM, Oldham RAA, Hari P, et al. Development of novel immunotherapies for multiple myeloma. Int J Mol Sci, 2016, 17 (9): 1506.

    [2] Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118 (17): 4519–4529.

    [3] Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28 (5): 1122–1128.

    [4] June CH, O’Connor RS, Kawalekar OU, et al. CART cell immunotherapy for human cancer. Science, 2018, 359 (6382): 1361–1365.

    [5] Hudecek M, Einsele H. Myeloma CARs are rolling into the clinical arena. Blood, 2016, 128 (13): 1667–1668.

    [6] Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood, 2017, 130 (24): 2594–2602.

    [7] Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010, 18 (4): 843–851.

    [8] Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011, 118 (18): 4817–4828.

    [9] Di Bernardo A, Macor P, Guarnotta C, et al. Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Exp Opin Biol Ther, 2010, 10 (6): 863–873.

    [10] Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res, 2017, 7 (8): 1637–1641.

    [11] Wang XL, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res, 2018, 24 (1): 106–119.

    [12] Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+normal lymphocytes. Blood, 2017, 130 (26): 2838–2847.

    [13] Jafari R, Zolbanin NM, Rafatpanah H, et al. Fc-fusion proteins in therapy: an updated view. Curr Med Chem, 2017, 24 (12): 1228–1237.

    [14] Ghose S, Hubbard B, Cramer SM. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol Bioeng, 2007, 96 (4): 768–779.

    [15] Ma QZ, De Marte L, Wang YW, et al. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc)for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther, 2004, 11 (4): 297–306.

    [16] Structural Genomics Consortium, Architecture et Fonction des Macromolécules Biologiques, Berkeley Structural Genomics Center, et al. Protein production and purification. Nat Methods, 2008, 5 (2): 135–146.

    [17] Chang ZL, Lorenzini MH, Chen XM, et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat Chem Biol, 2018, 14 (3): 317–324.

    [18] Irving BA, Weiss A. The cytoplasmic domain of the T cell receptorζchain is sufficient to couple to receptor-associated signal transduction pathways. Cell, 1991, 64 (5): 891–901.

    [19] Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA, 1991, 88 (20): 8905–8909.

    [20] Romeo C, Seed B. Cellular immunity to HIVactivated by CD4 fused to T cell or Fc receptor polypeptides. Cell, 1991, 64 (5): 1037–1046.

    [21] Marzio R, Mauël J, Betz-Corradin S. CD69 and regulatiof the immune function. Immunopharmacol Immunotoxicol, 1999, 21 (3): 565–582.

    [22] Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol, 1994, 12 (7): 1475–1483.

    [23] Beecham EJ, Ma QZ, Ripley R, et al. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J Immunother, 2000, 23 (6): 631–642.

    [24] Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity, 1998, 8 (1): 89–95.

This Article


CN: 11-1998/Q

Vol 36, No. 01, Pages 122-132

January 2020


Article Outline


  • 1 Materials and methods
  • 2 Results and analysis
  • 3 Discussion
  • References